Kalbe Farma Sets Up R&D Base in Singapore to Focus on Drug Development of Biopharmaceuticals
Indonesian-listed pharmaceutical company, PT Kalbe Farma Tbk. (Kalbe Farma) officially opened its office for research coordination and licensing in Singapore. The company focuses on research and development of biopharmaceuticals and other innovative products as well as diagnostic tools. Known as Innogene Kalbiotech Pte Ltd (Innogene), it is a wholly owned subsidiary of Kalbe. Innogene aims to specialise in oncology, intensive care, therapeutic and preventive vaccines.
To advance its vision to become a leading biopharmaceutical company, Innogene also collaborates with other local and international companies, researchers and institutions to acquire, develop and patent innovative pharmaceuticals and diagnostic products for the global market. They include Fraunhofer-Gessellschaft, Europe's largest applied science organisation to develop affordable diagnostic kits for Hepatitis C, Canada's YM BioSciences Inc to develop nimotuzumab also known as hR3 for treating brain tumour and Recombio, a Swiss company to develop a cancer vaccine, IE10, for the treatment of non small cell lung carcinoma and breast cancer. Innogene is also working with Singapore's Lynk Biotechnologies to develop and license out innovative products for application in different therapeutic classes.
Most read news
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.